midazolam has been researched along with Alogia in 4 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Each patient underwent baseline testing for motor function, aphasia, and left hemispatial neglect, after which intravenous midazolam was delivered until mild drowsiness was detected." | 9.10 | Reemergence of stroke deficits with midazolam challenge. ( Berman, MF; Bustillo, MA; Fitzsimmons, BF; Lazar, RM; Marshall, RS; Mohr, JP; Robinson, JV; Shah, J; Young, WL, 2002) |
| " Each patient underwent baseline testing for motor function and aphasia, after which intravenous midazolam was delivered until mild drowsiness was detected." | 5.10 | Midazolam challenge reinduces neurological deficits after transient ischemic attack. ( Berman, MF; Fitzsimmons, BF; Lazar, RM; Marshall, RS; Mohr, JP, 2003) |
| " Each patient underwent baseline testing for motor function, aphasia, and left hemispatial neglect, after which intravenous midazolam was delivered until mild drowsiness was detected." | 5.10 | Reemergence of stroke deficits with midazolam challenge. ( Berman, MF; Bustillo, MA; Fitzsimmons, BF; Lazar, RM; Marshall, RS; Mohr, JP; Robinson, JV; Shah, J; Young, WL, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shijo, T | 1 |
| Kanno, S | 1 |
| Shibuya, S | 1 |
| Oikawa, T | 1 |
| Ohnuma, A | 1 |
| Mochizuki, H | 1 |
| Lazar, RM | 3 |
| Berman, MF | 3 |
| Festa, JR | 1 |
| Geller, AE | 1 |
| Matejovsky, TG | 1 |
| Marshall, RS | 3 |
| Fitzsimmons, BF | 2 |
| Mohr, JP | 2 |
| Bustillo, MA | 1 |
| Young, WL | 1 |
| Shah, J | 1 |
| Robinson, JV | 1 |
2 trials available for midazolam and Alogia
| Article | Year |
|---|---|
Midazolam challenge reinduces neurological deficits after transient ischemic attack.
Topics: Adult; Aged; Aphasia; Dysarthria; Female; GABA Agonists; GABA-A Receptor Agonists; Humans; Ischemic | 2003 |
Reemergence of stroke deficits with midazolam challenge.
Topics: Adult; Aged; Aphasia; Female; GABA Modulators; Humans; Hypnotics and Sedatives; Male; Midazolam; Mid | 2002 |
2 other studies available for midazolam and Alogia
| Article | Year |
|---|---|
[Pure word deafness due to a localization-related seizure: a case study].
Topics: Adult; Aphasia; Cerebrum; Diffusion Magnetic Resonance Imaging; Electroencephalography; Epilepsies, | 2014 |
GABAergic but not anti-cholinergic agents re-induce clinical deficits after stroke.
Topics: Aged; Analysis of Variance; Aphasia; Cholinergic Antagonists; Cross-Over Studies; Double-Blind Metho | 2010 |